FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

ATTY, DOCKET NO. 33522-US-PCT 3352-US-PCT APPLICATION NO. 10/579,427 10/579,427 APPLICANT BAESCHLIN ET AL.

FILING DATE MAY 12, 2006 Sheet 1 of 1

Group 1621

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/SK/	AA	5,559,111	9/24/96	Göschke et al.	514	227	4/4/95
/SK/	AB	5,606,078	2/25/97	Göschke et al.	549	321	4/4/95
/SK/	AC	5,627,182	5/6/97	Göschke et al.	514	237	7/25/96
/SK/	AD	5,646,143	7/8/97	Göschke et al.	514	233	7/25/96
/SK/	AE	5,705,658	1/6/98	Göschke et al.	549	321	2/14/97
	AF						
	AG						
	АН						
	Al						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
/SK/	AM	WO 02/40007 A	5/23/02	PCT	1			
/SK/	AN	WO 03/103653 A	12/18/03	PCT				
	AO							
	AP							
	AQ							

/SK/	AR	Wood et al, Biochemical and B based design of aliskiren, a nov	liophysical Research Communicativel orally effective rennin inhibitor.	ions 308, pp. 698-705, "Structure- (2003)
/SK/	AS	Synthesis of Novel 2,7-Dialkyl.	ledicinal Chemistry Letters, Vol. 7 Substituted 5(S)-Amino-4(S)-Hydr etic inhibitors of Human Renin	, No. 21, pp 2735-2740, Design and oxy-8-Phenyl-Octanecarboxamides
	АТ			

*EXAMINER: *EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.